BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP

CenterBook Partners LP trimmed its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 14.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 185,491 shares of the company’s stock after selling 30,453 shares during the quarter. BioNTech makes up 0.9% of CenterBook Partners LP’s portfolio, making the stock its 18th biggest holding. CenterBook Partners LP owned 0.08% of BioNTech worth $18,293,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in BNTX. Vontobel Holding Ltd. increased its stake in shares of BioNTech by 17.9% during the 3rd quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company’s stock worth $7,110,000 after purchasing an additional 10,924 shares in the last quarter. Allianz SE increased its position in BioNTech by 635.0% during the second quarter. Allianz SE now owns 5,880 shares of the company’s stock worth $626,000 after buying an additional 5,080 shares in the last quarter. Dodge & Cox acquired a new position in shares of BioNTech in the second quarter worth $93,421,000. LBP AM SA lifted its position in shares of BioNTech by 15.7% in the third quarter. LBP AM SA now owns 353,329 shares of the company’s stock valued at $34,845,000 after acquiring an additional 47,859 shares in the last quarter. Finally, Lingohr Asset Management GmbH lifted its position in shares of BioNTech by 598.4% in the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company’s stock valued at $4,699,000 after acquiring an additional 40,821 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

BNTX has been the subject of several analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $134.00 target price on shares of BioNTech in a research note on Monday, November 3rd. Bank of America cut their price objective on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. TD Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective on the stock. in a report on Monday, February 2nd. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.10.

BioNTech Price Performance

BioNTech stock opened at $106.99 on Wednesday. The firm has a fifty day moving average of $103.34 and a 200-day moving average of $103.48. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $124.49. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.09 billion, a P/E ratio of -40.68 and a beta of 1.49.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.